Mycn: A Potential Drug Target Or Biomarker (G4613)

Target Name: MYCN

NCBI ID: G4613

MYCN

Mycn: A Potential Drug Target Or Biomarker

Mycn (class E basic helix-loop-helix protein 37) is a protein that is expressed in a wide range of tissues in the human body, including the brain, heart, and blood vessels. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will discuss the research on Mycn and its potential as a drug target or biomarker.

Mycn was first identified in the 1990s as a potential cytoskeletal protein that plays a role in the regulation of cell shape and movement. Since then, a number of studies have demonstrated that Mycn plays a critical role in the development and maintenance of tissues and organs, including the brain and heart.

One of the most significant functions of Mycn is its role in cell proliferation. Mycn has been shown to play a key role in the regulation of cell proliferation by allowing cells to move into a state of active growth and by regulating the production of new cells. In addition, Mycn has been shown to play a critical role in the regulation of cell differentiation, by ensuring that cells are able to transition from one type of cell to another.

Another important function of Mycn is its role in the regulation of cell migration. Mycn has been shown to play a key role in the regulation of cell movement, by allowing cells to move in specific directions and by regulating the formation of new blood vessels. This is important for the development of new tissues and organs, including the brain and heart.

In addition to its role in cell proliferation and differentiation, Mycn has also been implicated in a number of diseases. For example, studies have shown that high levels of Mycn are associated with the development of cancer, including breast cancer and lung cancer. Additionally, Mycn has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Despite these promising findings, much more research is needed to fully understand the role of Mycn in disease. One of the major challenges in studying Mycn is its complex structure and the difficulty in using it as a drug or biomarker. In addition, there is a lack of standardization in the experimental methods used to study Mycn, which can make it difficult to compare results from different studies.

In conclusion, Mycn is a protein that has the potential to be a drug target or biomarker. Its role in cell proliferation, differentiation, and migration makes it an important regulator of tissue and organ development, and its association with a number of diseases makes it a promising target for future research. Further studies are needed to fully understand the role of Mycn in disease and to develop effective ways to use it as a drug or biomarker.

Protein Name: MYCN Proto-oncogene, BHLH Transcription Factor

Functions: Positively regulates the transcription of MYCNOS in neuroblastoma cells

The "MYCN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYCN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets